Floatz logo

Linperlisib

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Beijing Tongren HospitalSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB
Tucidinostat
Ruijin Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Linperlisib is also rated in:

Indolent B-cell LymphomaDormant
BB
Indicative ·
65 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
61 / 100
View asset →
Extranodal Natural Killer/T Cell LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →